Latest Content

Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.

In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.

A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.

As pharmacists vocalize their willingness to fill in health care gaps, the integration of public health and emerging pharmacy professionals could be profound.

The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.

A persistence of pneumococcal meningitis among adults transformed the disease into a public health concern pharmacists fight on a population-wide scale.

An analysis found all-cause pneumonia Black, lower-income, and medically at-risk children still face substantially higher rates of hospitalization.

Data show postmenopausal women using hormone replacement therapy may have a 10% lower risk of developing dementia.

In this episode, Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, explore rhythms, routines and how they can make or break pharmacy team members.

The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.

Among patients with type 2 diabetes, researchers explore the effects of selecting additional therapy for GLP-1 treatment.

A cross-sectional survey links chronic fatigue, cognitive impairment, and menstrual irregularity to COVID-19 vaccination, with rates differing by brand.

A review of hospitalized patients with COVID-19 links female sex, severe acute illness, and intensive care unit admission to higher odds of long COVID.

Adults with type 1 diabetes who used Omnipod 5 Automated Insulin Delivery System maintained significant improvements in time in range and hemoglobin A1C.

Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.

A Bayesian meta-analysis finds patients regain half their treatment-associated weight loss within about 7.5 months of stopping semaglutide or tirzepatide.

AD109 significantly reduces breathing interruptions in adults with obstructive sleep apnea who could not tolerate or had refused CPAP therapy.

Jesse Goodman, MD, MPH, provides nuance regarding HHS’ suggestion to separate MMR combination vaccines as well as the looming elimination status review in November.

A population-level analysis finds that age, comorbidity burden, and long-term care residence continue to drive severe outcomes.

The combination outperformed ixekizumab alone on skin, joint, and weight outcomes through 52 weeks.

Once-weekly basal insulin has moved from an intriguing possibility to a new clinical reality.

Molly O’Shea, MD, FAAP, shares insights on MMR coverage, measles outbreaks, and the pharmacist’s role from the perspective of a pediatrician.

Data shows that those who stayed on tirzepatide had monthly health care costs well below those of untreated adults.

Pharmacy technician, Sharon Lucas, showcases how community pharmacy, clinical skills, and lifelong learning are transforming patient care.

In part 1 of our series, Thomas Lew, MD, ABIM, explores the optimal approaches to meandering vaccine hesitancy amid increasing measles cases.

For patients living with ASCVD, researchers find the optimal approach for ensuring medication adherence within patients’ statin regimens.

Data show adults who received the recombinant shingles vaccine had a lower cardiovascular burden than those who received the discontinued live vaccine.

Data show women are more likely to develop mental health disorders with type 2 diabetes, and men are more likely to develop cardiovascular disease.

New recommendations from the American Academy of Neurology and American Headache Society give providers clearer criteria for preventive migraine therapy.

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

The 4 key organizations regularly focusing on respiratory virus season released updated vaccine recommendations for 2026-2027.